Donor NK cells with low-dose IL-2 for AML relapse after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stem cell transplant and your leukemia has returned or is at high risk of returning (minimal residual disease positive).
- You have not had severe graft-versus-host disease (a complication where donor cells attack your body) after the transplant.
- Your organs (liver, kidneys, heart) are working well enough, as determined by standard tests.
- You are not pregnant or breastfeeding, and you agree to use effective birth control for at least 12 months after the infusion.
- You have not had certain other cancer treatments recently, like chemotherapy, radiation, or other cell therapies, within specific time frames.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
This trial tests a new treatment using special immune cells (called natural killer cells) made from stem cells to fight acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if these cells can safely help control or eliminate the leukemia.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests whether a special immune cell infusion (NK cells) from a half-matched family donor can help keep your AML in remission after initial chemotherapy. It is meant for people who have recently achieved their first remission and are otherwise healthy enough for a second round of chemo.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Hear when a new NK Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.